Clinical Trials Sponsored by VM Biopharma

Total 1388 results

Mereo BioPharma

Completed

A 6 Month Safety Extension Study of MBGS205

Hypogonadotropic Hypogonadism

United States
United BioPharma

Withdrawn

To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

HIV-1 Infection

China
Theravance Biopharma

Terminated

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (REDWOOD)

Parkinson's Disease (PD) | MSA | Symptomatic Neurogenic Orthostatic Hypotension | Pure Autonomic Failure (PAF)

United States, Spain, United Kingdom, Canada, France, Estonia, Australia, Israel, Denmark, Italy, Poland, New Zealand, Germany, Ukraine, Austria, Bulgaria, Portugal, Hungary, Russian Federation
DS Biopharma

Terminated

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Austria, Germany, Latvia, Poland
DS Biopharma

Completed

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

Atopic Dermatitis

United States, Canada, South Africa
Theravance Biopharma

Terminated

TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
CTI BioPharma

Completed

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post- Essential Thrombocythemia Myelofibrosis

United States, Spain, United Kingdom, Hungary, Korea, Republic of, France, Italy, Sweden
Theravance Biopharma

Completed

TD-0903 for ALI Associated With COVID-19

Acute Lung Injury (ALI) Associated With COVID-19 | Lung Inflammation Associated With COVID-19

Moldova, Republic of, United Kingdom, United States, Brazil, Finland, Romania, Ukraine
Theravance Biopharma

Terminated

TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)

United Kingdom
Theravance Biopharma

Completed

TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

United States
Theravance Biopharma

Completed

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

Symptomatic Neurogenic Orthostatic Hypertension | nOH

United States
Theravance Biopharma

Completed

A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)

Opioid Induced Constipation

United States
Theravance Biopharma

Completed

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Symptomatic Neurogenic Orthostatic Hypertension | nOH

United States
Theravance Biopharma

Completed

Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects

Healthy Adults, Elderly Subjects

United States
Theravance Biopharma

Completed

Single Ascending Dose Study of TD-1439 in Healthy Subjects

Healthy Subjects

United States
Theravance Biopharma

Completed

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

Healthy

United States
Theravance Biopharma

Completed

TD-1607 SAD Study in Healthy Subjects

Serious Infections Due to Known or Suspected Gram-positive Pathogens

United States
Theravance Biopharma

Completed

TD-9855 Mass Balance Study

Fibromyalgia | ADHD

United States
Theravance Biopharma

Completed

Drug-Drug Interaction (DDI) Study for TD-9855

Drug Drug Interaction (DDI)

United States
Theravance Biopharma

Completed

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

Inflammatory Bowel Disease

United States
Theravance Biopharma

Completed

TD-6450 SAD and MAD in Healthy Subjects

Hepatitis C

United States
Mereo BioPharma

Completed

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Bulgaria, Czechia, Germany, Hungary, Italy, Latvia, Poland, Romania, Russian Federation
CTI BioPharma

Withdrawn

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma | Leukemia

United States
CTI BioPharma

Terminated

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Completed

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States, United Kingdom, France, Italy, India, Germany, Hungary, Argentina, Uruguay, Russian Federation, Bulgaria, Costa Rica, Ecuador, Estonia, Mexico, Panama, Peru, Poland, Romania, Ukraine
CTI BioPharma

Withdrawn

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Lymphoma | Solid Tumor (Excluding CNS)

United States
DS Biopharma

Completed

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Germany
Espero Biopharma

Unknown

Tecarfarin Anti-Coagulation Trial (TACT) (TACT)

Thrombosis | Thromboembolism
Theravance Biopharma

Terminated

A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects

Gastrointestinal Motility Disorder

United States
Mereo BioPharma

Completed

The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers

Interaction

United Kingdom
Pronova BioPharma

Completed

The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

Dyslipidemia

United States
Recepta Biopharma

Completed

In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides

Metastatic Cancer

Brazil
Pronova BioPharma

Completed

Bioavailability of Omega-3 Food Supplement in Healthy Subjects

Biological Availability

United Kingdom
CTI BioPharma

Completed

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade | Lymphoma, Small Lymphocytic

United States
Theravance Biopharma

Completed

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

Chronic Constipation

United States
Recepta Biopharma

Completed

Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Brazil
Array BioPharma

Completed

A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Limerick BioPharma

Unknown

Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR

Insulin Resistance | Impaired Glucose Tolerance

United States
Limerick BioPharma

Completed

Safety and Tolerability of LIM-0705 in Healthy Male Subjects (LIM)

Healthy

Australia
CTI BioPharma

Completed

CT-2106 for the Second Line Treatment of Ovarian Cancer

Ovarian Cancer

France, United Kingdom, Italy
Pronova BioPharma

Completed

Omacor and Placebo in Carotid Plaque Stability

Cardiovascular Disease

United Kingdom
GenEros Biopharma Hangzhou Ltd

Recruiting

Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Advanced Solid Tumors

China
Elpiscience Biopharma Australia Pty. Ltd.

Recruiting

A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumor

Australia
HC Biopharma Inc.

Recruiting

A Study of HC006 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
UniQure Biopharma B.V.

Not yet recruiting

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

Fabry Disease
Arbutus Biopharma Corporation

Not yet recruiting

Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

Hepatitis B, Chronic
Synmosa Biopharma Corp.

Recruiting

Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation

Constipation

Taiwan
Hansa Biopharma AB

Recruiting

Imlifidase Prior to Kidney Transplant in Highly Sensitised Children (DINKY)

Kidney Transplantation in Highly Sensitized Patients

Spain, Finland, Sweden
Hansa Biopharma AB

Recruiting

Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys (ConfIdeSLTFU)

Kidney Transplantation in Highly Sensitized Patients

United States

Clinical Trials Sponsored by VM Biopharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations